Cancer immunotherapy: the beginning of the end of cancer?

Farkona S, Diamandis EP, Blasutig IM. · 2016

Read Cancer immunotherapy: the beginning of the end of cancer? by Farkona S, Diamandis EP, Blasutig IM. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4858828.txt.

Description

Sofia Farkona, Eleftherios P. Diamandis, and Ivan M. Blasutig surveyed cancer immunotherapy in BMC Medicine in 2016, asking whether it marks the beginning of the end of cancer. After years of weak results, immune-based care had just won real clinical ground. Routes include cancer vaccines, viruses that attack tumors, trained immune cells given back to patients, and antibodies that free immune brakes.

Antibodies blocking two brake proteins, CTLA-4 and PD1, led the breakthrough and sped work on new targets and drug mixes. Hard problems remain, from high cost to uneven patient response. The review weighs the surge with care, mapping where immune care stands and what must improve.

Catalog record

CREATORFarkona S, Diamandis EP, Blasutig IM.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE98 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4858828

Browse the full library · About the Tower of Babel